A Phase 4 interventional study of Mometasone Furoate Nasal Spray and fluticasone nasal spray in Allergic Rhinitis, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fluticasone in Rhinitis, Allergic — none open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic.
Among the 34 studies testing fluticasone in Rhinitis, Allergic, this one is the 14th largest by enrollment, is one of 3 that started in 2004, is one of 19 in phase 4, and was the 13th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →None of the 34 studies testing fluticasone in Rhinitis, Allergic is open now. The open studies under Rhinitis, Allergic, anywhere →
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 63 across the 34 interventional studies. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
21 studies in Rhinitis, Allergic by Organon & Co.: none open now, none under way, none of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 21 studies in Rhinitis, Allergic by Organon & Co., this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2004, is one of 6 in phase 4, and was the 11th registered.
Organon & Co.’s Rhinitis, Allergic studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fluticasone in Rhinitis, Allergic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 21 in Rhinitis, Allergic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a one-day single dose trial conducted to compare patient's preference for Nasonex® (mometasone) versus Flonase® nasal spray. Each patient was randomized to take one dose (2 sprays in each nostril) of Nasonex or Flonase. Thirty minutes later, each patient was to take one dose of the opposite medication. Questionnaires were given to each patient after each drug dose to evaluate patient product preference.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Mometasone Furoate Nasal Spray · Drug: fluticasone nasal spray
Drug: Mometasone Furoate Nasal Spray · Drug: fluticasone nasal spray
One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
Also known as: Nasonex, SCH 032088
One dose (2 sprays in each nostril) of fluticasone nasal spray
Also known as: Flonase®
Overall product preference based on subjects' answer to the question "which product do you prefer overall"
Time frame: On the study day, after dose of each product
Subject ratings for individual product attributes
Time frame: On the study day, after dose of each product
Subject rating for likely compliance with daily dosing,
Time frame: On the study day, after dose of each product
Subject preference for glass or plastic bottle
Time frame: On the study day, after dose of each product
Subject response to if they would want a prescription for their preferred product and if they would recommend the product
Time frame: On the study day, after dose of each product
Subject response to whether they preferred inhaled corticosteroid with or without aftertaste, and/or scent/odor,
Time frame: On the study day, after dose of each product
No study locations are listed for this record.
Ran from Dec 2004 to primary completion in Jan 2005, 1 month.
Of 34 phase 4 interventional studies under Rhinitis, Allergic, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 38. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone